Alexion Pharmaceuticals, a subsidiary of AstraZeneca, is a biopharmaceutical company focused on developing and delivering life-changing therapies for patients with rare diseases. The company specializes in orphan drugs, particularly in complement biology, addressing conditions in hematology, nephrology, neurology, and metabolic disorders. It aims to transform the lives of people affected by these devastating and ultra-rare conditions through pioneering scientific research and innovative medicines.